Business
Toxicology study
Toxicology study.
About this update from Immupharma Plc
[{"type":"text","content":"\n RNS Number : 0898Y Immupharma PLC 02 July 2008 \n \n\n\n\n\nFor Immediate Release\n\n\n2 July 2008\n\n\n\n\n\n \nImmuPharma PLC\n\nLong term toxicology studies confirmed the safety of LupuzorTM\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug discovery and development company, announces today LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.\n\n\nFor further information please contact: \n\n\n\n\nImmuPharma PLC: \n\n\n\n\n\n\n\nDimitri Dimitriou, Chief Executive Officer\n\n\n+44 20 7152 4080\n\n\n\n\nDr Robert Zimmer, President & Chief Scientific Officer\n\n\n+ 33 389 32 76 50\n\n\n\n\nRichard Warr, Chairman\n\n\n+44 20 7152 4080\n\n\n\n\n\n\n\n\n\n\n\n\nBuchanan Communications\n\n\n+ 44 20 7466 5000\n\n\n\n\nLisa Baderoon\n\n\n\n\n\n\n\nRebecca Skye Dietrich\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanmure Gordon & Co\n\n\n\n\n\n\n\nAndrew Burnett\n\n\n+44 151 243 0963\n\n\n\n\n\n\nFor further company information, visit www.immupharma.com\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END MSCRBMBTMMTMTFP \n ","length":4703,"tagName":"div"}]